Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63


The Discovery of a Novel Phosphodiesterase (PDE) 4B-Preferring Radioligand for Positron Emission Tomography (PET) Imaging.

Zhang L, Chen L, Beck EM, Chappie TA, Coelho RV, Doran SD, Fan KH, Helal CJ, Humphrey JM, Hughes Z, Kuszpit K, Lachapelle EA, Lazzaro JT, Lee C, Mather RJ, Patel NC, Skaddan MB, Sciabola S, Verhoest PR, Young JM, Zasadny K, Villalobos A.

J Med Chem. 2017 Oct 26;60(20):8538-8551. doi: 10.1021/acs.jmedchem.7b01050. Epub 2017 Oct 9.


Discovery and Characterization of (R)-6-Neopentyl-2-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-one (PF-06462894), an Alkyne-Lacking Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator Profiled in both Rat and Nonhuman Primates.

Stepan AF, Claffey MM, Reese MR, Balan G, Barreiro G, Barricklow J, Bohanon MJ, Boscoe BP, Cappon GD, Chenard LK, Cianfrogna J, Chen L, Coffman KJ, Drozda SE, Dunetz JR, Ghosh S, Hou X, Houle C, Karki K, Lazzaro JT, Mancuso JY, Marcek JM, Miller EL, Moen MA, O'Neil S, Sakurada I, Skaddan M, Parikh V, Smith DL, Trapa P, Tuttle JB, Verhoest PR, Walker DP, Won A, Wright AS, Whritenour J, Zasadny K, Zaleska MM, Zhang L, Shaffer CL.

J Med Chem. 2017 Sep 28;60(18):7764-7780. doi: 10.1021/acs.jmedchem.7b00604. Epub 2017 Sep 13.


Preclinical Evaluation of 18F-PF-05270430, a Novel PET Radioligand for the Phosphodiesterase 2A Enzyme.

Chen L, Nabulsi N, Naganawa M, Zasadny K, Skaddan MB, Zhang L, Najafzadeh S, Lin SF, Helal CJ, Boyden TL, Chang C, Ropchan J, Carson RE, Villalobos A, Huang Y.

J Nucl Med. 2016 Sep;57(9):1448-53. doi: 10.2967/jnumed.115.171454. Epub 2016 May 19.


The discovery and characterization of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor potentiator N-{(3S,4S)-4-[4-(5-cyano-2-thienyl)phenoxy]tetrahydrofuran-3-yl}propane-2-sulfonamide (PF-04958242).

Shaffer CL, Patel NC, Schwarz J, Scialis RJ, Wei Y, Hou XJ, Xie L, Karki K, Bryce DK, Osgood SM, Hoffmann WE, Lazzaro JT, Chang C, McGinnis DF, Lotarski SM, Liu J, Obach RS, Weber ML, Chen L, Zasadny KR, Seymour PA, Schmidt CJ, Hajós M, Hurst RS, Pandit J, O'Donnell CJ.

J Med Chem. 2015 May 28;58(10):4291-308. doi: 10.1021/acs.jmedchem.5b00300. Epub 2015 May 14.


Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator.

Zhang L, Balan G, Barreiro G, Boscoe BP, Chenard LK, Cianfrogna J, Claffey MM, Chen L, Coffman KJ, Drozda SE, Dunetz JR, Fonseca KR, Galatsis P, Grimwood S, Lazzaro JT, Mancuso JY, Miller EL, Reese MR, Rogers BN, Sakurada I, Skaddan M, Smith DL, Stepan AF, Trapa P, Tuttle JB, Verhoest PR, Walker DP, Wright AS, Zaleska MM, Zasadny K, Shaffer CL.

J Med Chem. 2014 Feb 13;57(3):861-77. doi: 10.1021/jm401622k. Epub 2014 Jan 22.


Design and selection parameters to accelerate the discovery of novel central nervous system positron emission tomography (PET) ligands and their application in the development of a novel phosphodiesterase 2A PET ligand.

Zhang L, Villalobos A, Beck EM, Bocan T, Chappie TA, Chen L, Grimwood S, Heck SD, Helal CJ, Hou X, Humphrey JM, Lu J, Skaddan MB, McCarthy TJ, Verhoest PR, Wager TT, Zasadny K.

J Med Chem. 2013 Jun 13;56(11):4568-79. doi: 10.1021/jm400312y. Epub 2013 May 28.


The synthesis and in vivo evaluation of [18F]PF-9811: a novel PET ligand for imaging brain fatty acid amide hydrolase (FAAH).

Skaddan MB, Zhang L, Johnson DS, Zhu A, Zasadny KR, Coelho RV, Kuszpit K, Currier G, Fan KH, Beck EM, Chen L, Drozda SE, Balan G, Niphakis M, Cravatt BF, Ahn K, Bocan T, Villalobos A.

Nucl Med Biol. 2012 Oct;39(7):1058-67. doi: 10.1016/j.nucmedbio.2012.03.011. Epub 2012 May 8.


[(18)F]FLT-PET imaging does not always "light up" proliferating tumor cells.

Zhang CC, Yan Z, Li W, Kuszpit K, Painter CL, Zhang Q, Lappin PB, Nichols T, Lira ME, Affolter T, Fahey NR, Cullinane C, Spilker M, Zasadny K, O'Brien P, Buckman D, Wong A, Christensen JG.

Clin Cancer Res. 2012 Mar 1;18(5):1303-12. doi: 10.1158/1078-0432.CCR-11-1433. Epub 2011 Dec 14.


PF-03732010: a fully human monoclonal antibody against P-cadherin with antitumor and antimetastatic activity.

Zhang CC, Yan Z, Zhang Q, Kuszpit K, Zasadny K, Qiu M, Painter CL, Wong A, Kraynov E, Arango ME, Mehta PP, Popoff I, Casperson GF, Los G, Bender S, Anderes K, Christensen JG, VanArsdale T.

Clin Cancer Res. 2010 Nov 1;16(21):5177-88. doi: 10.1158/1078-0432.CCR-10-1343. Epub 2010 Sep 9.


PF-00477736 mediates checkpoint kinase 1 signaling pathway and potentiates docetaxel-induced efficacy in xenografts.

Zhang C, Yan Z, Painter CL, Zhang Q, Chen E, Arango ME, Kuszpit K, Zasadny K, Hallin M, Hallin J, Wong A, Buckman D, Sun G, Qiu M, Anderes K, Christensen JG.

Clin Cancer Res. 2009 Jul 15;15(14):4630-40. doi: 10.1158/1078-0432.CCR-08-3272. Epub 2009 Jul 7.


MicroPET detection of regional brain activation induced by colonic distention in a rat model of visceral hypersensitivity.

Ohashi K, Ichikawa K, Chen L, Callahan M, Zasadny K, Kurebayashi Y.

J Vet Med Sci. 2008 Jan;70(1):43-9.


Accurate dosimetry in 131I radionuclide therapy using patient-specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation.

Dewaraja YK, Wilderman SJ, Ljungberg M, Koral KF, Zasadny K, Kaminiski MS.

J Nucl Med. 2005 May;46(5):840-9.


131I-tositumomab therapy as initial treatment for follicular lymphoma.

Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, Regan D, Kison P, Fisher S, Kroll S, Wahl RL.

N Engl J Med. 2005 Feb 3;352(5):441-9.


Bias reduction in correlation of radiation-absorbed dose with response.

Koral KF, Zasadny K, Wahl RL.

J Nucl Med. 2004 Jul;45(7):1271; author reply 1271-2. No abstract available.


Diabetes Decreases FDG Accumulation in Primary Lung Cancer.

Torizuka T, Zasadny KR, Wahl RL.

Clin Positron Imaging. 1999 Oct;2(5):281-287.


FDG-PET Determination of Metabolically Active Tumor Volume and Comparison with CT.

Zasadny KR, Kison PV, Francis IR, Wahl RL.

Clin Positron Imaging. 1998 Mar;1(2):123-129.


A positron-emitting internal marker for identification of normal tissue by positron emission tomography: phantom studies and validation in patients.

Thomas CT, Meyer CR, Koeppe RA, Kalemkerian GP, Fisher SJ, Dull TL, Zasadny KR, Wahl RL.

Mol Imaging Biol. 2003 Mar-Apr;5(2):79-85.


Update on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients.

Koral KF, Dewaraja Y, Li J, Lin Q, Regan DD, Zasadny KR, Rommelfanger SG, Francis IR, Kaminski MS, Wahl RL.

J Nucl Med. 2003 Mar;44(3):457-64.


FDG metabolism and uptake versus blood flow in women with untreated primary breast cancers.

Zasadny KR, Tatsumi M, Wahl RL.

Eur J Nucl Med Mol Imaging. 2003 Feb;30(2):274-80. Epub 2002 Nov 20.


Expression of hexokinase II and Glut-1 in untreated human breast cancer.

Brown RS, Goodman TM, Zasadny KR, Greenson JK, Wahl RL.

Nucl Med Biol. 2002 May;29(4):443-53.


Tumor-absorbed-dose estimates versus response in tositumomab therapy of previously untreated patients with follicular non-Hodgkin's lymphoma: preliminary report.

Koral KF, Dewaraja Y, Clarke LA, Li J, Zasadny KR, Rommelfanger SG, Francis IR, Kaminski MS, Wahl RL.

Cancer Biother Radiopharm. 2000 Aug;15(4):347-55.


Initial results for Hybrid SPECT--conjugate-view tumor dosimetry in 131I-anti-B1 antibody therapy of previously untreated patients with lymphoma.

Koral KF, Dewaraja Y, Li J, Barrett CL, Regan DD, Zasadny KR, Rommelfanger SG, Francis IR, Kaminski MS, Wahl RL.

J Nucl Med. 2000 Sep;41(9):1579-86.


Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience.

Kaminski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M, Regan D, Fisher S, Gutierrez J, Kroll S, Stagg R, Tidmarsh G, Wahl RL.

Blood. 2000 Aug 15;96(4):1259-66.


Metabolic response of non-Hodgkin's lymphoma to 131I-anti-B1 radioimmunotherapy: evaluation with FDG PET.

Torizuka T, Zasadny KR, Kison PV, Rommelfanger SG, Kaminski MS, Wahl RL.

J Nucl Med. 2000 Jun;41(6):999-1005.


I-131 anti-B1 therapy/tracer uptake ratio using a new procedure for fusion of tracer images to computed tomography images.

Koral KF, Li J, Dewaraja Y, Barrett CL, Regan DD, Zasadny KR, Rommelfanger SG, Francis IR, Kaminski MS, Wahl RL.

Clin Cancer Res. 1999 Oct;5(10 Suppl):3004s-3009s.


Reevaluation of the standardized uptake value for FDG: variations with body weight and methods for correction.

Sugawara Y, Zasadny KR, Neuhoff AW, Wahl RL.

Radiology. 1999 Nov;213(2):521-5.


Splenic fluorodeoxyglucose uptake increased by granulocyte colony-stimulating factor therapy: PET imaging results.

Sugawara Y, Zasadny KR, Kison PV, Baker LH, Wahl RL.

J Nucl Med. 1999 Sep;40(9):1456-62.


Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer.

Brown RS, Leung JY, Kison PV, Zasadny KR, Flint A, Wahl RL.

J Nucl Med. 1999 Apr;40(4):556-65.


Germ cell tumor: differentiation of viable tumor, mature teratoma, and necrotic tissue with FDG PET and kinetic modeling.

Sugawara Y, Zasadny KR, Grossman HB, Francis IR, Clarke MF, Wahl RL.

Radiology. 1999 Apr;211(1):249-56.


Rapid detection of human infections with fluorine-18 fluorodeoxyglucose and positron emission tomography: preliminary results.

Sugawara Y, Braun DK, Kison PV, Russo JE, Zasadny KR, Wahl RL.

Eur J Nucl Med. 1998 Sep;25(9):1238-43.


Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience.

Wahl RL, Zasadny KR, MacFarlane D, Francis IR, Ross CW, Estes J, Fisher S, Regan D, Kroll S, Kaminski MS.

J Nucl Med. 1998 Aug;39(8 Suppl):21S-27S.


Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation.

Wahl RL, Kroll S, Zasadny KR.

J Nucl Med. 1998 Aug;39(8 Suppl):14S-20S.


Immunolymphoscintigraphy in breast cancer: evaluation using 131I-labeled monoclonal antibody B72.3.

Fig LM, Brown RS, von Moll L, Appelman HD, Stevens R, Harness J, August D, Sondak VK, Chang AE, Zasadny KR, Fisher SJ, Johnson JW, Wicha MS, Colcher D, Lichter AS, Wahl RL.

Nucl Med Biol. 1998 Apr;25(3):251-60.


Deadtime correction for two multihead Anger cameras in 131I dual-energy-window-acquisition mode.

Koral KF, Zasadny KR, Ackermann RJ, Ficaro EP.

Med Phys. 1998 Jan;25(1):85-91.


Demonstration of accuracy and clinical versatility of mutual information for automatic multimodality image fusion using affine and thin-plate spline warped geometric deformations.

Meyer CR, Boes JL, Kim B, Bland PH, Zasadny KR, Kison PV, Koral K, Frey KA, Wahl RL.

Med Image Anal. 1997 Apr;1(3):195-206.


Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.

Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, Estes J, Tuck M, Regan D, Fisher S, Glenn SD, Wahl RL.

J Clin Oncol. 1996 Jul;14(7):1974-81.


CT-SPECT fusion plus conjugate views for determining dosimetry in iodine-131-monoclonal antibody therapy of lymphoma patients.

Koral KF, Zasadny KR, Kessler ML, Luo JQ, Buchbinder SF, Kaminski MS, Francis I, Wahl RL.

J Nucl Med. 1994 Oct;35(10):1714-20.


Standardized uptake values of FDG.

Leskinen-Kallio S, Minn H, Zasadny KR.

J Nucl Med. 1994 Sep;35(9):1564-6. No abstract available.


Predictors of toxicity in treating patients with neuroblastoma by radiolabeled metaiodobenzylguanidine.

Sisson JC, Shapiro B, Hutchinson RJ, Carey JE, Zasadny KR, Zempel SA, Normolle DP.

Eur J Nucl Med. 1994 Jan;21(1):46-52.


Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation.

Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R.

J Clin Oncol. 1993 Nov;11(11):2101-11.


Supplemental Content

Loading ...
Support Center